Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial is evaluating the efficacy and side effect of orelabrutinib and
sintilimab as possible treatments for relapsed or refractory central nervous system lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
First Affiliated Hospital of Zhejiang University First People's Hospital of Hangzhou Huizhou Municipal Central Hospital Jinhua Central Hospital Jinhua People's Hospital Second Affiliated Hospital of Wenzhou Medical University Sir Run Run Shaw Hospital Wenzhou Central Hospital Yinzhou Hospital Affiliated to Medical School of Ningbo University Zhejiang Provincial People's Hospital Zhejiang Provincial Tongde Hospital